Monograph of Dapagliflozin

Introduction/Overview

Dapagliflozin is a selective inhibitor of the sodium‑glucose cotransporter 2 (SGLT2) that modulates renal glucose handling and exerts systemic metabolic effects. The clinical relevance of this agent has expanded beyond glycaemic control to encompass cardiovascular and renal protection in patients with type 2 diabetes mellitus (T2DM) and heart failure with reduced ejection fraction (HFrEF). For medical and pharmacy students, an understanding of dapagliflozin’s pharmacodynamic and pharmacokinetic properties, therapeutic indications, and safety considerations is essential for optimal patient care and therapeutic decision‑making.

Learning objectives

• Describe the chemical classification and structural features of dapagliflozin.
• Explain the mechanism by which dapagliflozin modulates glucose homeostasis and other systemic effects.
• Summarize the pharmacokinetic profile and dosing considerations in various patient populations.
• Identify approved therapeutic indications, off‑label uses, and evidence‑based benefits.
• Recognize common adverse events, serious risks, and major drug interactions.
• Apply special‑population knowledge to clinical practice, including renal, hepatic, pediatric, geriatric, and pregnancy considerations.

Classification

Drug Class

Dapagliflozin belongs to the class of sodium–glucose cotransporter 2 (SGLT2) inhibitors, a subgroup of antihyperglycaemic agents that act on the proximal renal tubule. It is commonly referred to as a “gliflozin” due to its shared chemical scaffolding with other drugs in this class.

Chemical Classification

The molecule is a 4‑(4‑(pyridin‑3‑yl)‑piperidin‑1‑yl)‑4‑oxo‑2‑pyridone derivative. It features a pyridone core connected to a piperidine ring that is substituted with a pyridyl side chain. Dapagliflozin is structurally analogous to empagliflozin and canagliflozin, yet it possesses distinct physicochemical properties that influence its potency and selectivity for SGLT2 over SGLT1.

Mechanism of Action

Pharmacodynamics

Dapagliflozin selectively binds to the luminal face of the SGLT2 transporter located on the brush border of the proximal convoluted tubule. By occupying the glucose‑binding pocket, it impedes Na⁺‑dependent reabsorption of glucose, resulting in increased urinary glucose excretion (UGE). The inhibition is reversible and dose‑dependent, with an IC₅₀ of approximately 0.4 nM for SGLT2 and >1000 nM for SGLT1, indicating high selectivity.

The reduction in systemic glucose load leads to modest decreases in fasting and post‑prandial plasma glucose concentrations. Concurrently, the osmotic diuresis induced by UGE contributes to mild reductions in intravascular volume, which may underlie observed blood pressure lowering effects.

Receptor Interactions and Cellular Effects

Beyond glucose transport inhibition, dapagliflozin may influence multiple downstream pathways. The increased glucosuria can alter glucagon‑like peptide‑1 (GLP‑1) secretion, potentially enhancing insulin sensitivity. Additionally, the osmotic diuresis and natriuretic effect may reduce preload and afterload, thereby improving cardiac function in HFrEF. These physiological changes have been associated with decreased hospitalization rates for heart failure and renal events, although the precise molecular mechanisms remain an area of ongoing research.

Pharmacokinetics

Absorption

Following oral administration, dapagliflozin is absorbed rapidly, with peak plasma concentrations (C_max) occurring approximately 1.5 h post‑dose. The absolute bioavailability is estimated at 87 %, and food does not significantly alter overall exposure but may delay absorption slightly.

Distribution

The drug distributes extensively throughout the body, achieving a volume of distribution (V_d) of roughly 120 L. Plasma protein binding is about 30 %, predominantly to albumin, which permits a substantial free fraction available for interaction with SGLT2 transporters.

Metabolism

Dapagliflozin is primarily metabolised by cytochrome P450 3A4 (CYP3A4) via oxidative pathways, yielding inactive metabolites that are excreted unchanged. Minor contributions from CYP2C9 and CYP2C19 have been noted, but these pathways are not clinically significant in the setting of standard dosing.

Excretion

Renal excretion constitutes the main elimination route, with approximately 85 % of the administered dose recovered in urine as unchanged drug or metabolites. Hepatic clearance is minimal. The half‑life (t_1/2) is approximately 12 h, allowing for once‑daily dosing.

Dosing Considerations

In patients with normal renal function, a maintenance dose of 10 mg orally once daily is typical. For moderate renal impairment (eGFR 30–59 mL/min/1.73 m²), the same dose may be maintained, although efficacy may be attenuated. In severe renal impairment (eGFR <30 mL/min/1.73 m²) or end‑stage renal disease on dialysis, dapagliflozin is not recommended due to substantially reduced efficacy and increased risk of adverse events.

Therapeutic Uses/Clinical Applications

Approved Indications

• Adjunctive therapy for T2DM in adults to improve glycaemic control, in combination with diet, exercise, and other antihyperglycaemic agents.
• Reduction of cardiovascular death, all‑cause mortality, and hospitalization for heart failure in patients with HFrEF, irrespective of diabetes status.
• Reduction of renal endpoints (progression to end‑stage kidney disease, doubling of serum creatinine) in adults with T2DM and chronic kidney disease (CKD) stages 1–3.

Off‑Label Uses

Clinicians have occasionally employed dapagliflozin in patients with type 1 diabetes mellitus (T1DM) for glycaemic adjunctive therapy, although the risk of diabetic ketoacidosis (DKA) is heightened. In heart failure with preserved ejection fraction (HFpEF), emerging data suggest potential benefits, yet formal approval is pending. Additionally, dapagliflozin has been explored in metabolic syndrome and obesity management, but robust evidence is lacking.

Adverse Effects

Common Side Effects

• Genitourinary infections (vaginal candidiasis, urinary tract infections)
• Volume depletion symptoms (orthostatic hypotension, dizziness)
• Polyuria and nocturia
• Hypoglycaemia when combined with insulin or sulfonylureas

Serious or Rare Adverse Reactions

• Acute genital infection requiring systemic therapy
• Severe volume depletion leading to renal impairment or hypotension
• Diabetic ketoacidosis, particularly in T1DM or in patients with low insulin doses
• Increases in serum LDL‑cholesterol and triglycerides, though HDL may rise

Black Box Warnings

Risks of serious genital or urinary tract infections, volume depletion, and diabetic ketoacidosis are highlighted. Patients are advised to monitor for symptoms and adjust therapy accordingly.

Drug Interactions

Major Drug‑Drug Interactions

• Strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) may increase dapagliflozin exposure, potentially enhancing adverse effects.
• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine) may reduce plasma concentrations, decreasing efficacy.
• Concurrent use with other antihyperglycaemic agents (especially insulin or sulfonylureas) can elevate hypoglycaemia risk.
• Diuretics (loop or thiazide) may potentiate volume depletion.

Contraindications

Patients with hypersensitivity to dapagliflozin or any component of the formulation, severe renal impairment, or those undergoing dialysis should not receive the drug. Additionally, patients with a history of recurrent genital infections may experience exacerbation.

Special Considerations

Use in Pregnancy/Lactation

Data from animal studies indicate potential teratogenic effects; therefore, dapagliflozin is classified as pregnancy category D. It is not recommended during pregnancy or lactation unless the potential benefit outweighs the risk. Lactation data are limited, and caution is advised.

Pediatric Considerations

Clinical trials in children with T2DM are limited. The drug is currently not approved for pediatric use, and dosing adjustments are not established. Off‑label use should be restricted to clinical trials or compassionate use under strict monitoring.

Geriatric Considerations

Elderly patients may exhibit reduced renal function and altered volume status, increasing the likelihood of adverse events. Dose adjustments are usually unnecessary unless renal impairment is present; however, careful monitoring for hypotension and infection is recommended.

Renal/Hepatic Impairment

In patients with moderate renal impairment, efficacy may be modestly reduced, but safety remains acceptable. Severe renal impairment (<30 mL/min/1.73 m²) or dialysis renders the drug ineffective. Hepatic impairment is not a major concern, but caution is advised in cirrhotic patients due to potential alterations in drug metabolism.

Summary/Key Points

• Dapagliflozin selectively inhibits renal SGLT2, promoting glucosuria and modest glycaemic reduction.
• Its pharmacokinetic profile supports once‑daily oral administration, with renal excretion predominating.
• Approved indications include T2DM, HFrEF, and CKD progression prevention; off‑label uses are emerging but unverified.
• Common adverse events revolve around genitourinary infections and volume depletion; serious risks include DKA and renal dysfunction.
• Drug interactions primarily involve CYP3A4 modulators and concurrent antihyperglycaemics; contraindications encompass severe renal impairment and pregnancy.
• Special populations require individualized assessment: pregnancy, lactation, pediatrics, geriatrics, and renal/hepatic impairment.
• Clinical monitoring should focus on renal function, volume status, infection signs, and glycaemic control, particularly when combined with insulin or sulfonylureas.

References

1. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
2. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
3. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
4. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
5. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
6. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
7. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
8. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.